Register Log-in Investor Type

Healthcare News

This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term care facilities, and medical equipment and supplies. Companies in this sector include Astra Zeneca, Pfizer and Roche Holding.

04 Mar 2024

Bellevue Healthcare Trust has another year of underperformance

Bellevue Healthcare Trust (BBH) released its annual report for the 12 months ending 30 November 2023. Over the period BBH reported a negative NAV total return of -12.7%, and a negative share price total return of -12.7%. This compares to the -7.1% negative return of its benchmark, the MSCI World Healthcare Index total return. This […]

02 Jan 2024
BioPharma Credit leads new $315m loan to Sebela

BioPharma Credit provides update on LumiraDx loan

On December 29, 2023, LumiraDx Limited announced that Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting had been appointed as joint administrators of two of its subsidiaries, LumiraDx Group Limited and LumiraDx International Limited, which hold the assets of the LumiraDx group. Following their appointment, the administrators have entered into a sale and […]

03 Nov 2023

QuotedData’s weekly news update 3rd November 2023

Thank you to everyone that listened in today, whether you watched the Zoom live, on Facebook or on YouTube. In this week’s show, James Carthew covered the week’s top stories: • RTW / Arix  (0:47) Andrew McHattie picked up on the positive reaction from markets in response to the Bank of England holding interest rates, […]

01 Nov 2023

RTW Biotech Opportunities to acquire Arix Bioscience

RTW Biotech Opportunities (RTW) has announced that it will acquire Arix Bioscience. The transaction is expected to deliver RTW with an expected pro-forma net asset value of approximately $550 million, an increase of 63% The deal will enhance RTW’s profile, provide increased liquidity potential, a more efficient cost base, and a re-rating opportunity. Arix shareholders […]

04 Aug 2023

QuotedData’s weekly news show 4th August 2023

Thank you to everyone that listened in today, whether you watched the Zoom live, on Facebook or on YouTube. In this week’s show, James Carthew covered the week’s top stories: • ThomasLloyd Energy Impact (0.38) • BioPharma Credit (6:44) Andrew McHattie spoke about Trixtax Big Box REIT & HydrogenOne (10:31). This week’s interview was with […]

17 Jul 2023

BB Biotech set to gain on Argenx positive trial news

BB Biotech should be able to report a significant increase in NAV tomorrow as a result of a positive trial outcome – with a corresponding c.25%increase in share price – by one of its largest holdings, the US-listed, Belgian company Argenx. The news represents an important fillip for the Swiss investment company, which has seen […]

22 Jun 2023

The big question with Vulcan’s C.T. Fitzpatrick and Jupiter’s Ben Whitmore

As fears that high interest rates may persist, we examine how a potential recession could affect equities with Alliance Trust Stock Pickers Ben Whitmore and C.T. Fitzpatrick in the latest of our ‘The big question’ interviews. previous story | next story

07 Jun 2023

Another down year for Worldwide Healthcare

Worldwide Healthcare Trust (WWH) has released its annual report for the year ended 31 March 2023. The company’s net asset value per share total return was -0.1% and the share price total return was -4.1%, underperforming the benchmark MSCI World Health Care Index measured on a net total return, sterling adjusted basis, which returned +2.5% […]

22 May 2023

The Big Question – Does macro matter? with Andrew Wellington and Brian Kersmanc

In Alliance Trust’s latest manager interview, Brian Kersmanc and Andrew Wellington share their views on the most important drivers of stock returns and to what extent the macro influences their investment decisions. Filmed: April 2023  

19 May 2023

QuotedData’s weekly news show 19th May 2023

Thank you to everyone that listened in today, whether you watched the Zoom live, on Facebook or on YouTube. In this week’s show, James Carthew covered the week’s top stories: • abrdn Japan (0:36) • BioPharma Credit (8:02) ​• Gresham House Energy Storage (13:12) This week’s interview was with Michael Anderson from Aquila Capital European Renewables – […]

26 Apr 2023

QuotedData’s morning briefing 26 April 2023

RTW Venture Fund Limited announced that Abdera Therapeutics has completed its $142M Series A and Series B financing rounds in which it participated. Abdera is a privately held pre-clinical stage biopharmaceutical company leveraging antibody engineering to design and develop new precision radiopharmaceuticals for cancer. The company is building a pipeline of potentially best-in-class therapies for […]

31 Mar 2023

Strong outperformance from RTW Venture aided by realisations

RTW Venture (RTW) has published its annual results for the year ended 31 December 2022, During the year, RTW’s NAV declined by -10.2% (from US$363.0m or US$1.71 per share to US$326.1m or US$1.54 per share) with the main detractor being the markdown in Ji Xing (c. -2.2% contribution), after the IPO was delayed due to […]

08 Mar 2023

QuotedData’s morning briefing 8 March 2023

In QuotedData’s morning briefing 8 March 2023: Syncona’s (SYNC’s) portfolio company Autolus Therapeutics has announced its operational and financial results for the full year ended December 31, 2022. Key highlights included: The FELIX study of obe-cel in relapsed/refractory (r/r) adult acute lymphoblastic leukemia (ALL) met its primary endpoint; remains on track for a next data […]

09 Dec 2022

RTW gets boost from Prometheus trial success

RTW Venture Fund has drawn investors’ attention to positive data updates on two clinical trials of Prometheus Biosciences, Inc. (NASDAQ: RXDX), its third largest holding, representing about 7.5% of NAV. Prometheus is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for […]

09 Dec 2022

QuotedData’s Morning briefing 9 December 2022

In QuotedData’s Morning briefing 9 December 2022: Syncona’s (SYNC’s) portfolio company Autolus Therapeutics Plc has announced the pricing of its underwritten public offering, in the US, of 75m American Depositary Shares (ADSs). These represent 75m ordinary shares and were issued at a price of US$2.00 per ADS, for total gross proceeds of approximately US$150m (£122.5m). […]

08 Dec 2022

RTW Venture backs Apogee

RTW was a co-lead in a $149m Series B financing round for Apogee Therapeutics, LLC, a biotechnology company focused on immunological and inflammatory disorders. RTW Venture participated in the fundraise but we have not been not told what its contribution was. Proceeds from the financing will be used to support Apogee’s plans to advance its […]

23 Nov 2022

QuotedData’s morning briefing 23 November 2022

In QuotedData’s morning briefing 23 November 2022: Worldwide Healthcare (WWH) has announced its interim results for the six months ended 30 September 2022. During the period, WWH provided an NAV total return of 3.1%, modestly outperforming its benchmark, the MSCI World Healthcare Index, which returned 2.1% during the period. In absolute terms, net asset value […]

21 Nov 2022

BioPharma Credit provides senior loan to Immunocore

BioPharma Credit (BPCR) has announced that, together with BioPharma Credit Investments V, it has entered into a senior secured loan agreement with Immunocore Limited. BPCR will invest up to US$50m and BioPharma-V will also invest up to an additional US$50m. Based in the UK, Immunocore is a publicly traded biopharmaceutical company with a current market […]

18 Nov 2022

Conviction Life Sciences publishes prospectus for £100m IPO

A new Guernsey domiciled investment company, Conviction Life Sciences (CLSC), published a prospectus on 16 November 2022 for its initial public offering (IPO). The prospectus is availale here. The IPO is targeting gross proceeds of £100m and CLSC plans to list on the main market of the London Stock Exchange. It is expected that CLSC’s […]

28 Oct 2022

QD view – Biotech sector is ripe for investment but collectives are the way forward

Biotechnology is an exciting and potentially rewarding sector for investment but for the private investor it is also risky and probably best addressed through collective investment vehicles. After all, development of new drugs is hugely expensive (and thus funding-dependent), scientifically uncertain and fraught with operational challenges and pitfalls. And adding to this is the fact […]

04 Oct 2022

BB Biotech’s enters Q4 with NAV rise on Myovant buyout offer

BB Biotech saw an almost 3% rise in its NAV yesterday to CHF51/share, helped by a 36% jump in the share price in one of its holdings – Myovant – triggered by a cash buy-out offer. BB Biotech’s share price, however, was largely unchanged at CHF52.8, which has had the effect of reducing the investment […]

23 Sep 2022

BB Biotech’s latest investment hints at broader strategy

Switzerland’s BB Biotech has opened a new investment position in Rivus Pharmaceuticals, a privately held US biotech developing a mitochondrial-based approach to obesity and cardio-metabolic disease. This was made as part of a $132m Series B financing that is notable for its size and the top-tier syndicate of healthcare specialist investors who have participated. The […]

16 Sep 2022

QuotedData’s morning briefing 16 September 2022

In QuotedData’s morning briefing 16 September 2022: RTW Venture’s (RTW’s) portfolio company, Third Harmonic Bio Inc., has completed its initial public offering (IPO) and has listed on Nasdaq (ticker: THRD). The upsized issue raised US$185.3m by offering around 10.7m shares at US$17.00 per share. Third Harmonic Bio is a clinical-stage biotechnology company developing a first-in-class, […]

22 Jul 2022

QD view – Is the tide finally turning for biotech?

In early 2021, it looked like the pandemic had been a breakthrough moment for the biotechnology sector. The sector had been critical in the development of Covid-19 vaccines, using new and innovation gene sequencing, while developments in oncology promised a treatment revolution. Share prices were riding high and specialist investment trusts had enjoyed two years […]

15 Jul 2022

BB Biotech shares rise as sector sees signs of recovery

BB Biotech shares closed yesterday at CHF 57 per share, down 26.5% in the year-to-date period, but crucially up by 12% since mid-June when the shares hit a recent nadir of CHF51 per share. NAV, at CHF49.95 per share, is down by 9.95% year-to-date (YTD), but has gained 22% from its recent nadir of CHF40.9 […]

16 Jun 2022

Syncona well-placed to back its portfolio through adverse market

Syncona’s results for the financial year ended 31 March 2022 show an NAV total return of just 0.3%. However, this was a long way ahead of the -12% return on the NASDAQ Biotechnology Index. A significant NAV uplift achieved through the sale of Gyroscope to Novartis and multiple successful private financings offset the decline in […]

27 May 2022

Major underperformance for Worldwide Healthcare

Following the announcement earlier today that it has terminated its placing programme (click here to read more), Worldwide Healthcare (WWH) has now announced its annual results for the year ended 31 March 2022. These show that, following the previous year’s strong returns, both on an absolute and on a relative basis, the year under review […]

27 May 2022

QuotedData’s morning briefing 27 May 2022

In QuotedData’s morning briefing 27 May 2022: Worldwide Healthcare (WWH) has announced that it is terminating its placing programme, which was established on 13 July 2021, with immediate effect. WWH expects to publish its annual results later today and, if the placing programme was still in effect, this would have required WWH to publish a […]

13 May 2022

QuotedData’s morning briefing 13 May 2022

In QuotedData’s morning briefing 13 May 2021: Barings Emerging EMEA Opportunities (BEMO) has announced that Maria Szczesna, one of its investment managers, and a member of the Barings EMEA Team, has decided to step down from her portfolio management responsibilities to return to her home country for family reasons. Maria will remain with BEMO until […]

09 May 2022

BB Biotech remains resilient as biotech markets worsen

BB Biotech (SWX:BION) has continued to show a resilient performance this year, a period that has proved to be extremely challenging for biotech investing – indeed the sector is now considered to be experiencing its most severe bear market for more than two decades. BB Biotech’s shares closed on Friday at CHF 56.00, down 23% […]

Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.

You live in…

You are a…